Low-Dose Nitrous Oxide Shows Benefit for Resistant Depression Batya Swift Yasgur, MA, LSW Medscape.com, 2021 June 17, 2021 A 1-hour treatment with a low concentration of nitrous oxide, commonly known as "laughing gas," appears to relieve symptoms of treatment-resistant major depression (TRMD), with effects lasting as long as several weeks, new research suggests. In a trial with a crossover design, investigators randomly assigned 28 patients with severe TRMD to receive a single 1-hour inhalation of placebo or nitrous oxide once a month over a 3-month period. Participants received an inhalation of placebo; a 25% concentration of nitrous oxide; and a 50% concentration of nitrous oxide. Sessions were [...]
Lire la suiteCannabis and synaptic reprogramming of the developing brain Anissa Bara, Jacqueline- Marie N. Ferland, Gregory Rompala, Henrietta Szutorisz and Yasmin L. Hurd Nature Reviews | Neuroscience, 2021, https://doi.org/10.1038/s41583-021-00465-5 Abstract Recent years have been transformational in regard to the perception of the health risks and benefits of cannabis with increased acceptance of use. This has unintended neurodevelopmental implications given the increased use of cannabis and the potent levels of Δ9-tetrahydrocannabinol today being consumed by pregnant women, young mothers and teens. In this Review, we provide an overview of the neurobiological effects of cannabinoid exposure during prenatal/perinatal and adolescent periods, in which the endogenous cannabinoid system plays [...]
Lire la suiteContre les stupéfiants, Macron prône l’acharnement thérapeutique 19 avr. 2021 Par Camille Polloni et Ellen Salvi - Mediapart.fr Jadis ouvert à la dépénalisation du cannabis, le chef de l’État se dit aujourd’hui favorable à une politique antidrogues sévère, visant à « harceler les trafiquants et les dealers », mais aussi les usagers. Quitte à s’enfoncer dans une impasse. Du cannabis saisi et photographié à Marseille lors d'une visite de Gérald Darmanin, le 25 février. © Nicolas Tucat/AFP C’est une profession de foi digne d’un ministre de l’intérieur en exercice, promesses et objectifs chiffrés à l’appui, mais le président de la République en est pour une fois [...]
Lire la suiteN° 4173 _____ ASSEMBLÉE NATIONALE CONSTITUTION DU 4 OCTOBRE 1958 QUINZIÈME LÉGISLATURE Enregistré à la Présidence de l’Assemblée nationale le 18 mai 2021. PROPOSITION DE LOI relative à la lutte contre le commerce illégal de drogues, (Renvoyée à la commission des affaires sociales, à défaut de constitution d’une commission spéciale dans les délais prévus par les articles 30 et 31 du Règlement.) présentée par Mesdames et Messieurs Éric COQUEREL, Jean-Félix ACQUAVIVA, Ugo BERNALICIS, Alexis CORBIÈRE, Elsa FAUCILLON, Hubert JULIEN-LAFERRIÈRE, François-Michel LAMBERT, Jean-Baptiste MOREAU, Danièle OBONO, Matthieu ORPHELIN, Richard RAMOS, Jean-Hugues RATENON, Muriel RESSIGUIER, Bénédicte TAURINE, Michèle VICTORY, Patrick VIGNAL, députés. EXPOSÉ DES MOTIFS MESDAMES, MESSIEURS, Cette proposition de loi se donne pour objectif de [...]
Lire la suiteBibliographie : Kétamine Dr Christian Sueur, GRECC, (mai 2021) Kétamine en Psychiatrie : 1 - 3 Usages thérapeutiques en médecine psychédélique : 4 Kétamine et psychose : 5 - 6 Kétamine et traitement de la dépression : 7 - 20 Kétamine et prise en charge de l’idéation suicidaire : 21 - 22 Kétamine et traitement de la dépression chez les enfants et adolescents : 23 - 24 Kétamine et prise en charge des troubles psychotraumatiques (PTSD) : 25 - 27 Ketamine et addictions : 28 - 29 Kétamine et sevrage des opiacés : 30 Kétamine et prise en charge de la douleur : 31 - 32 Kétamine et prise en charge de [...]
Lire la suiteA qualitative and quantitative account of patient’s experiences of ketamine and its antidepressant properties Rachael L. Sumner, Emme Chacko, Rebecca McMillan, Meg J. Spriggs, Christie Anderson, James Chen, Amelia French, SungHun Jung, Akshaya Rajan, Gemma Malpas, John Hay, Rhys Ponton, Suresh D. Muthukumaraswamy and Frederick Sundram Journal of Psychopharmacology, 2021, 1-16 Doi : 10.1177/0269881121998321 Abstract Background : Ketamine is central to one of the most rapidly growing areas of neuroscientific research into novel treatments for depression. Limited research has indicated that the psychedelic properties of ketamine may play a role in its antidepressant effects. Aim : The aim of the current study was to explore the [...]
Lire la suiteCase in Context : Tourette Syndrome Kirsten MÜLLER-VAHL Cannabis and Cannabinoid Research, 2021, 1-4. doi : 10.1089/can.2021.0005 Dr. Kirsten Müller-Vahl: Mr. Miller,* thank you very much for taking part in this interview. I would like to ask you to first explain how Tourette syndrome has impacted your life and what restrictions you experienced. Miller: The first tics appeared approximately when I was 5 years old. Especially during my childhood, I had more intense vocal tics consisting of different sounds and noises. Later on, I suffered mainly from motor tics such as shaking my head or poking my tongue out. People did not understand why I [...]
Lire la suiteWithin-treatment changes in a novel addiction treatment program using traditional Amazonian medicine David M. O’Shaughnessy , Ilana Berlowitz, Robin Rodd, Zoltán Sarnyai and Frances Quirk Therapeutic Advances in Psychopharmacology, 2021, Vol. 11, 1–18 DOI : 10.1177/2045125320986634 Abstract Aims : The therapeutic use of psychedelics is regaining scientific momentum, but similarly psychoactive ethnobotanical substances have a long history of medical (and other) uses in indigenous contexts. Here we aimed to evaluate patient outcomes in a residential addiction treatment center that employs a novel combination of Western and traditional Amazonian methods. Methods : The study was observational, with repeated measures applied throughout treatment. All tests were administered in [...]
Lire la suiteMDMA-assisted therapy for severe PTSD : a randomized, double-blind, placebo-controlled phase 3 study Jennifer M. Mitchell, Michael Bogenschutz, Alia Lilienstein, Charlotte Harrison, Sarah Kleiman6, Kelly Parker-Guilbert7, Marcela Ot’alora G., Wael Garas, Casey Paleos, Ingmar Gorman 11, Christopher Nicholas12, Michael Mithoefer5,9,13, Shannon Carlin, Bruce Poulter 8,9, Ann Mithoefer9, Sylvestre Quevedo2,14, Gregory Wells 14, Sukhpreet S. Klaire, Bessel van der Kolk16, Keren Tzarfaty9, Revital Amiaz17, Ray Worthy18, Scott Shannon, Joshua D. Woolley2, Cole Marta20, Yevgeniy Gelfand21, Emma Hapke, Simon Amar, Yair Wallach, Randall Brown11, Scott Hamilton25, Julie B. Wang5, Allison Coker 1,5, Rebecca Matthews, Alberdina de Boer5, Berra Yazar-Klosinski, Amy Emerson and Rick Doblin Nature Medicine | www.nature.com/naturemedicine, 2021, 1-12. doi : [...]
Lire la suiteCannabidiol (CBD) repurposing as antibacterial: promising therapy of 1 CBD plus polymyxin B against superbugs Nathália Abichabki, Luísa V. Zacharias, Natália C. Moreira, Fernando Bellissimo-Rodrigues, Fernanda L. Moreira, Jhohann R. L. Benzi1, Tânia M. C. Ogasawara, Joseane C. Ferreira, Leonardo R. L. Pereira, Gilberto Ú. L. Braga, Camila M. Ribeiro, Fernando R. Pavan, Antonio W. Zuardi, Jaime E. C. Hallak, José A. S. Crippa, Vera L. Lanchote, Rafael Cantón, Ana Lúcia C. Darini, Leonardo N. Andrade bioRxiv preprint, 2021 doi : 10.1101/2021.04.12.439341 Abstract : Multidrug-resistant (MDR) and extensively drug-resistant (XDR) bacteria are a major worldwide public health problem. In the last decades, resistance to [...]
Lire la suite